Informacja

Drogi użytkowniku, aplikacja do prawidłowego działania wymaga obsługi JavaScript. Proszę włącz obsługę JavaScript w Twojej przeglądarce.

Tytuł pozycji:

hTERT Transduction Extends the Lifespan of Primary Pediatric Low-Grade Glioma Cells While Preserving the Biological Response to NGF.

Tytuł:
hTERT Transduction Extends the Lifespan of Primary Pediatric Low-Grade Glioma Cells While Preserving the Biological Response to NGF.
Autorzy:
Franzese O; Department of Systems Medicine, University of Rome Tor Vergata, Rome, Italy.
Di Francesco AM; Institute of Internal Medicine, Periodic Fever and Rare Diseases Center, Fondazione Policlinico A. Gemelli, IRCCS, Rome, Italy.
Meco D; UOC di Oncologia Pediatrica, 'Fondazione Policlinico Universitario A. Gemelli', IRCCS, Rome, Italy.
Graziani G; Department of Systems Medicine, University of Rome Tor Vergata, Rome, Italy.
Cusano G; UOC di Oncologia Pediatrica, 'Fondazione Policlinico Universitario A. Gemelli', IRCCS, Rome, Italy.
Levati L; Molecular Oncology Laboratory, IDI-IRCCS, Rome, Italy.
Riccardi R; UOC di Oncologia Pediatrica, 'Fondazione Policlinico Universitario A. Gemelli', IRCCS, Rome, Italy.
Ruggiero A; UOC di Oncologia Pediatrica, 'Fondazione Policlinico Universitario A. Gemelli', IRCCS, Rome, Italy.
Źródło:
Pathology oncology research : POR [Pathol Oncol Res] 2021 Apr 02; Vol. 27, pp. 612375. Date of Electronic Publication: 2021 Apr 02 (Print Publication: 2021).
Typ publikacji:
Journal Article
Język:
English
Imprint Name(s):
Publication: 2021- : Lausanne, Switzerland : Frontiers Media S. A.
Original Publication: Budapest, Hungary : Science Press, c1995-
MeSH Terms:
Brain Neoplasms*
Glioma*
Tumor Cells, Cultured*
Nerve Growth Factor/*metabolism
Telomerase/*genetics
Transduction, Genetic/*methods
Cell Culture Techniques/methods ; Humans
References:
Proc Natl Acad Sci U S A. 1986 Aug;83(16):6184-7. (PMID: 3090553)
J Neurooncol. 2002 Sep;59(3):199-205. (PMID: 12241115)
Mol Immunol. 2013 Jun;54(2):181-92. (PMID: 23287597)
J Cell Physiol. 2019 May;234(5):6820-6830. (PMID: 30417351)
Am J Med Genet. 1999 Mar 26;89(1):38-44. (PMID: 10469435)
Clin Cancer Res. 2011 Jul 15;17(14):4650-60. (PMID: 21610151)
J Clin Oncol. 2007 Feb 20;25(6):682-9. (PMID: 17308273)
Acta Neuropathol. 2006 Jun;111(6):569-78. (PMID: 16614861)
Nat Cell Biol. 2007 May;9(5):493-505. (PMID: 17450133)
J Biol Chem. 2014 Aug 1;289(31):21205-16. (PMID: 24939843)
Acta Neuropathol. 2016 Jun;131(6):803-20. (PMID: 27157931)
Neuro Oncol. 2010 Dec;12(12):1257-68. (PMID: 20861086)
PLoS One. 2009;4(4):e5209. (PMID: 19365568)
Oncogene. 2005 Oct 27;24(47):7073-83. (PMID: 16103883)
Cytotechnology. 2004 Jun;45(1-2):33-8. (PMID: 19003241)
J Clin Immunol. 2000 Jul;20(4):257-67. (PMID: 10939713)
Nat Rev Mol Cell Biol. 2015 May;16(5):281-98. (PMID: 25907612)
Hum Pathol. 1998 Jun;29(6):599-603. (PMID: 9635680)
Childs Nerv Syst. 2001 Sep;17(9):503-11. (PMID: 11585322)
Int J Oncol. 2005 Aug;27(2):525-35. (PMID: 16010436)
Chemotherapy. 2018 Mar 13;63(2):64-75. (PMID: 29533947)
Annu Rev Neurosci. 1996;19:463-89. (PMID: 8833451)
Glia. 2009 Oct;57(13):1386-92. (PMID: 19229990)
Neuro Oncol. 2008 Dec;10(6):968-80. (PMID: 19074980)
Acta Neuropathol. 2007 Aug;114(2):97-109. (PMID: 17618441)
Sci Rep. 2016 Apr 04;6:23903. (PMID: 27041678)
Cancers (Basel). 2019 Jun 08;11(6):. (PMID: 31181803)
Am J Physiol Gastrointest Liver Physiol. 2015 Nov 15;309(10):G801-6. (PMID: 26405114)
Brain. 2016 Feb;139(Pt 2):404-14. (PMID: 26767384)
Pharmaceuticals (Basel). 2016 Apr 28;9(2):. (PMID: 27136566)
Nature. 2002 Jun 27;417(6892):949-54. (PMID: 12068308)
Cell Prolif. 2007 Feb;40(1):14-23. (PMID: 17227292)
Mol Ther. 2000 Apr;1(4):376-82. (PMID: 10933956)
Anticancer Res. 2014 Jun;34(6):2859-67. (PMID: 24922649)
Cancer. 2009 Dec 15;115(24):5761-70. (PMID: 19813274)
J Biol Chem. 2001 May 25;276(21):17864-70. (PMID: 11359788)
Histopathology. 2000 Nov;37(5):437-44. (PMID: 11119125)
Bioessays. 1998 Feb;20(2):137-45. (PMID: 9631659)
J Biomed Biotechnol. 2009;2009:910610. (PMID: 19644551)
Mech Ageing Dev. 2005 Aug;126(8):855-65. (PMID: 15992610)
Cancer Res. 2001 Jul 1;61(13):4956-60. (PMID: 11431323)
Acta Neuropathol. 2011 Mar;121(3):407-20. (PMID: 21113787)
J Immunol. 2013 Oct 1;191(7):3744-52. (PMID: 23997212)
J Clin Neurosci. 2005 Feb;12(2):166-8. (PMID: 15749420)
Mol Cell Neurosci. 2008 Aug;38(4):595-606. (PMID: 18585058)
Cancer Cell. 2006 Dec;10(6):459-72. (PMID: 17157787)
Oncol Rep. 2007 Dec;18(6):1571-6. (PMID: 17982646)
Neuro Oncol. 2003 Oct;5(4):228-34. (PMID: 14565158)
Neurorehabil Neural Repair. 2011 Jul-Aug;25(6):512-20. (PMID: 21444653)
Arch Ital Biol. 2011 Jun;149(2):275-82. (PMID: 21702000)
Genes Dev. 1998 Oct 1;12(19):3008-19. (PMID: 9765203)
Oncogene. 2002 Jan 21;21(4):494-502. (PMID: 11850774)
Oncol Lett. 2018 Jan;15(1):533-537. (PMID: 29391888)
Contributed Indexing:
Keywords: NGF (nerve growth factor); differentiation; hTERT; low-grade glioma; senescence
Substance Nomenclature:
0 (NGF protein, human)
9061-61-4 (Nerve Growth Factor)
EC 2.7.7.49 (Telomerase)
Entry Date(s):
Date Created: 20210714 Date Completed: 20211220 Latest Revision: 20211220
Update Code:
20240105
PubMed Central ID:
PMC8262147
DOI:
10.3389/pore.2021.612375
PMID:
34257579
Czasopismo naukowe
The neurotrophin nerve growth factor (NGF) modulates the growth of human gliomas and is able to induce cell differentiation through the engagement of tropomyosin receptor kinase A (TrkA) receptor, although the role played in controlling glioma survival has proved controversial. Unfortunately, the slow growth rate of low-grade gliomas (LGG) has made it difficult to investigate NGF effects on these tumors in preclinical models. In fact, patient-derived low-grade human astrocytoma cells duplicate only a limited number of times in culture before undergoing senescence. Nevertheless, replicative senescence can be counteracted by overexpression of hTERT, the catalytic subunit of telomerase, which potentially increases the proliferative potential of human cells without inducing cancer-associated changes. We have extended, by hTERT transduction, the proliferative in vitro potential of a human LGG cell line derived from a pediatric pilocytic astrocytoma (PA) surgical sample. Remarkably, the hTERT-transduced LGG cells showed a behavior similar to that of the parental line in terms of biological responses to NGF treatment, including molecular events associated with induction of NGF-related differentiation. Therefore, transduction of LGG cells with hTERT can provide a valid approach to increase the in vitro life-span of patient-derived astrocytoma primary cultures, characterized by a finite proliferative potential.
Competing Interests: The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
(Copyright © 2021 Franzese, Di Francesco, Meco, Graziani, Cusano, Levati, Riccardi and Ruggiero.)

Ta witryna wykorzystuje pliki cookies do przechowywania informacji na Twoim komputerze. Pliki cookies stosujemy w celu świadczenia usług na najwyższym poziomie, w tym w sposób dostosowany do indywidualnych potrzeb. Korzystanie z witryny bez zmiany ustawień dotyczących cookies oznacza, że będą one zamieszczane w Twoim komputerze. W każdym momencie możesz dokonać zmiany ustawień dotyczących cookies